Edge Therapeutics, a Berkeley Heights, New Jersey-based biotechnology company, has entered into a supply agreement and an amended and restated development agreement with Oakwood Laboratories, a Cleveland, Ohio-based specialty pharmaceutical company, for the commercial manufacturing of EG-1962 (nimodipine), for treating aneurysmal subarachnoid hermorrhage. Oakwood Laboratories is focused on sustained-release injectable products and also provides contract manufacturing services.

EG-1962, a polymeric microparticle containing nimodipine suspended in a diluent of sodium hyaluronate, is an orphan drug and fast-track product designated by the US Food and Drug Administration. It is currently in Phase III development.

Source: Edge Therapeutics